Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
anniversary, area, back, Biopharma, buy, chemical, chronic, countermeasure, DAA, dasabuvir, domestic, Europe, EXVIERA, FASB, Harvoni, heading, infection, ingredient, intensified, landscape, liver, NASH, open, paritaprevir, pretax, RBV, residual, sofusbuvir, transition, transitioning, unmet, unused, VIEKIRAX, viral, VOE
Removed:
assume, bacterial, began, beginning, bilateral, certainty, conclusion, conditioned, Congressional, Cubicin, Cubist, death, enacted, extend, extension, factor, Forest, generically, governance, hospital, Idenix, impasse, inclusive, incremental, incrementally, influenzae, Japan, Jumpstart, mentioned, modification, NASDAQ, negotiate, obligate, oral, outset, Pfizer, pneumonia, potency, preceding, procuring, prove, registrational, reimburse, remeasured, renewal, resistance, respiratory, responsibility, separable, sequestration, size, specific, spent, Teflaro, tract, Tygacil, unsafe, vancomycin, Vibativ, Wyeth, Zyvox
Filing tables
Filing exhibits
Related press release
ENTA similar filings
Filing view
External links